Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

dopamine Hydrochloride in 5% dextrose injection, USP Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DOPAMINE HYDROCHLORIDE IN DEXTROSE INJECTION safely and effectively. See full prescribing information for DOPAMINE HYDROCHLORIDE IN DEXTROSE INJECTION.

DOPAMINE HYDROCHLORIDE IN DEXTROSE injection, for intravenous use
Initial U.S. Approval: 1974

INDICATIONS AND USAGE

Dopamine HCl in Dextrose Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. (1)

DOSAGE AND ADMINISTRATION

  • Correct hypovolemia, acidosis, and hypoxia prior to use. (2.1)
  • Administer in a large vein with an infusion pump preferably in an intensive care setting. (2.1)
  • Recommended starting dosage in adults and pediatric patients is 2 to 5 mcg/kg/minute as a continuous intravenous infusion. Titrate in 5 to 10 mcg/kg/minute increments based on hemodynamic response and tolerability, up to not more than 50 mcg/kg/minute. (2.2)
  • See the Full Prescribing Information for important preparation instructions and drug incompatibilities. (2.3)

DOSAGE FORMS AND STRENGTHS

Following strengths of Dopamine Hydrochloride in 5% Dextrose Injection, USP, are supplied in LifeCare flexible single-dose plastic containers (each 100 mL contains 5 grams of hydrous dextrose in Water for Injection): (3)

  • 800 mcg/mL (250 and 500 mL)
  • 1600 mcg/mL (250 and 500 mL)
  • 3200 mcg/mL (250 mL)

CONTRAINDICATIONS

Patients with pheochromocytoma. (4)

WARNINGS AND PRECAUTIONS

  • Tissue ischemia: Severe peripheral and visceral vasoconstriction can occur. Address hypovolemia prior to use, monitor extremities, and infuse into large vein. (5.1)
  • Cardiac arrhythmias: Monitor closely. (5.2)
  • Hypotension after abrupt discontinuation: Gradually reduce infusion rate while expanding blood volume with intravenous fluids. (5.3)
  • Severe hypersensitivity reactions due to sodium metabisulfite excipient: May cause anaphylaxis including life-threatening or less severe asthmatic episodes in susceptible individuals. (5.4)

ADVERSE REACTIONS

The most common adverse reaction is localized vasoconstriction due to extravasation. (6)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Halogenated anesthetics: Can sensitize the myocardium to the effects of dopamine and can produce ventricular arrhythmias and hypertension. (7)
  • MAO inhibitors: Risk of severe hypertension. Reduce recommended Dopamine HCl in Dextrose Injection dosage. (7)
  • Tricyclic antidepressants: Risk of hypertension. Monitor blood pressure. (7)
  • Vasopressors: Risk of severe hypertension. Monitor blood pressure. (7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2021

Show All Hide All
Show All Hide All
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event
Pfizer Safety

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at
(800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.